Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx (Nasdaq: LUNG) reported Q1 2026 results: revenue $20.6M (down 9% YoY; -12% constant currency), with U.S. $13.3M and international $7.3M (China-related decline; ex-China international +22% YoY). Gross margin was 78%, net loss $13.7M (EPS -$0.33), cash $61.6M. Full-year 2026 guidance: revenue $90M–$92M, gross margin ~75%, operating expenses $113M–$115M. Company refinanced debt with a 5-year interest-only facility extending maturity to 2031.
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:15 AM PT / 11:15 AM ET. A live and archived webcast will be available in the Investors section of the company website.
Pulmonx (Nasdaq: LUNG) will report first quarter 2026 financial results after the close of trading on Wednesday, April 29, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a live and archived webcast available in the Investors section of the Pulmonx website.
Pulmonx (Nasdaq: LUNG) reported fourth quarter and full year 2025 results on March 4, 2026. Total 2025 revenue was $90.5M, up 8% year-over-year; Q4 revenue was $22.6M, down 5% year-over-year. Gross margin was 78% in Q4 and 74% for 2025. The company refinanced debt, securing up to $60M under a new five-year interest-only credit facility and implemented cost restructuring. Cash and marketable securities were $69.8M at year-end, down about $32M year-over-year. 2026 guidance calls for revenue of $90M–$92M, ~75% gross margin, and operating expenses of $113M–$115M.
Pulmonx (Nasdaq: LUNG) closed a five-year credit facility with Perceptive Advisors for up to $60 million on March 4, 2026. The facility funds a $40 million term loan drawn at closing to refinance existing debt and a conditional $20 million undrawn option through end of 2027.
The loan is interest-only until its 2031 maturity, bears interest at one-month Term SOFR (3.75% floor) plus 7.0%, and allows 2.0% paid-in-kind interest at the company’s option for three years.
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.
Pulmonx (Nasdaq: LUNG) announced that on December 1, 2025 it granted equity awards under its 2025 Inducement Plan totaling 1,625,000 shares to two executives hired in Q4 2025, including CFO Derrick Sung.
The awards comprise 1,225,000 RSUs (Mr. Sung received 1,200,000 RSUs) that vest 25% after one year and then quarterly over three years. Mr. Sung also received up to 400,000 PSUs subject to a time-based vesting schedule (33% at one year, then quarterly over two years) and a 60-trading-day average closing price performance condition. The Inducement Plan was adopted by the board in November 2025 and complies with Nasdaq Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported third quarter 2025 results for the period ended September 30, 2025: total revenue $21.5M (+5% vs Q3 2024; +4% constant currency), with U.S. revenue $14.0M (+1% YoY) and international revenue $7.5M (+15% YoY; +9% constant currency). Gross profit was $16.1M and gross margin 75%. Operating expenses were $30.4M and net loss was $14.0M ($0.34 per share). Adjusted EBITDA loss was $8.2M. Cash and cash equivalents totaled $76.5M at quarter end. Pulmonx updated full-year 2025 guidance to $89M–$90M revenue, ~73% gross margin, and $125M–$126M operating expenses (including ~$21M stock-based compensation).
Pulmonx (NASDAQ: LUNG) announced a management transition and preliminary third quarter 2025 revenue on October 27, 2025. Glen French is reappointed President and CEO effective immediately; Derrick Sung will become COO and CFO effective November 3, 2025. Two executives, Steve Williamson and Mehul Joshi, resigned and will serve as advisors through December 1, 2025. The company reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million. Third quarter 2025 financial results and a conference call were rescheduled for November 12, 2025 at 1:30 p.m. PT / 4:30 p.m. ET. The revenue figure is preliminary and subject to revision when full results are released.
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.